Missing Data Issues at the FDA Center for Biologics Evaluation and Research

Author： Scott John   Hsu Henry  

Publisher： Taylor & Francis Ltd

ISSN： 1054-3406

Source： Journal of Biopharmaceutical Statistics, Vol.21, Iss.2, 2011-03, pp. : 196-201

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Handling Missing Data in Vaccine Clinical Trials for Immunogenicity and Safety Evaluation

By Li Xiaoming   Wang William   Liu Guanghan   Chan Ivan  

Journal of Biopharmaceutical Statistics, Vol. 21, Iss. 2, 2011-03 ,pp. : 294-310

Taylor & Francis Ltd

Access to resources Recommend Favorite

Statistical Test for Evaluation of Biosimilarity in Variability of Follow-On Biologics

By Hsieh Tsung-Cheng  

Journal of Biopharmaceutical Statistics, Vol. 20, Iss. 1, 2010-01 ,pp. : 75-89

Taylor & Francis Ltd

Access to resources Recommend Favorite

Nonparametric Tests for Evaluation of Biosimilarity in Variability of Follow-on Biologics

By        

Journal of Biopharmaceutical Statistics, Vol. 24, Iss. 6, 2014-11 ,pp. : 1239-1253

Taylor & Francis Ltd

Access to resources Recommend Favorite

US FDA issues not approvable letter for istradefylline.

By  

Inpharma, Vol. 1, Iss. 1628, 2008-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Lindane: FDA issues public health advisory

By  

Inpharma, Vol. 1, Iss. 1381, 2003-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite